Bisphosphonates are the mainstay of osteoporosis treatment. Despite the fact that bisphosphonates have a relatively good safety record and are tolerated well by the majority of patients, serious adverse events have been associated with their use. A 41-year-old man had been diagnosed with osteoporosis and had taken etidronate 200 mg/day daily for 2 years due to the judgmental error. He was referred for the management of refractory bone pain and generalized muscle ache. Serum calcium, phosphate, 25-hydroxyvitamin D (25(OH)D), and immunoreactive parathyroid hormone (iPTH) were within normal range. Plain X-ray showed multiple fractures. Whole body bone scan confirmed multiple sites of increased bone uptakes. Tetracycline-labeled bone biopsy showed typical findings of osteomalacia. He was diagnosed with iatrogenic, etidronate-induced osteomalacia. The patient received daily parathyroid hormone (PTH) injection for 18 months. PTH effectively reverses impaired bone mineralization caused by etidronate misuse. Currently, he is doing well without bone pain. Bone mineral density significantly increased, and the increased bone uptake was almost normalized after 18 months. This case seems to suggest that human PTH (1-34) therapy, possibly in association with calcium and vitamin D, is associated with important clinical improvements in patients with impaired bone mineralization due to the side effect of bisphosphonate. (Endocrinol Metab 27:247-250, 2012) 
INTRODUCTION
Bisphosphonates are the mainstay of osteoporosis treatment.
The efficacy of bisphosphonates has been well demonstrated [1] [2] [3] .
Though bisphosphonates have a relatively good safety record and are tolerated well by the majority of patients, serious adverse events have been associated with their use. Hence, some unadvertised aspects of bisphosphonates, including their long half-life and their effects on bone physiology need to be addressed. Furthermore, clinicians need to know how to treat a patient who has experienced side effect of this drug. Recently, many studies have emphasized a long-term side effect of bisphosphonate [4] [5] [6] . It has been reported that etidronate, one of the first generation of bisphosphonate medication rarely used now, may lead impairment of bone mineralization and subsequent drug-induced osteomalacia [6] [7] [8] .
We report a case of a patient who developed osteomalacia because of etidronate misuse and was treated effectively by using parathyroid hormone (PTH), an anabolic agent.
CASE REPORT
A 41-year-old man with a history of cerebral palsy presented with a 1-year history of proximal muscle weakness and generalized bone pain. The symptom of general pain began 1 year ago, especially at the hip and the leg. The pain progressively worsened, and for the past 3 months, the pain interfered with the patient's sleep. The patient had no history of alcohol, smoking, or hypertension. The patient was previously diagnosed with cerebral palsy, and used wheelchair to move. The patient was diagnosed with osteoporosis at another hospital 3 years ago and since then took eti-http://www.enm-kes.org The dual energy X-ray absorptiometry (DEXA) suggested osteopenia, with T-score of lumbar spine and femur -2.0 and -1.6, respectively. WBBS showed multiple sites with increased uptake, including bilateral rib, cervical spine, lumbar spine, bilateral femur, right fibula, and right sacrum (Fig. 1 ).
Including the above findings, there were no evidence of malignancy and other causes of osteomalacia, and the patient was suspected with metabolic bone disease; therefore, tetracycline double labeling was planned, but since the patient could not wait 3 weeks due to severe pain, single labeling bone biopsy was performed at the iliac crest in September 16th, 2009. The findings of bone biopsy were consistent with osteomalacia (Fig. 2) . After combining the above findings, the patient was ultimately diagnosed with osteomalacia due to etidronate misuse. We first prescribed (Cal-D-vita, Bayer Korea, Seoul, Korea) (calcium carbonate 1,500 mg and cholecalciferol 400 IU) to supplement calcium and vitamin D; however, it was replaced by Calico (Hanmi Pharmaceuticals, Seoul, Korea) (calcitriol 1 μg) for its strong potency and quick response. In this patient, bone turnover was extremely suppressed and the function of osteoblast, as well as osteoclast, was severely impaired.
We considered intermittent PTH treatment [12] as the next approach because many previous report already showed that it could reverse bisphosphonate-related low bone turnover and some disease with impairment of mineralization [6, 13, 14] . Recently, Jamal and Hodsman [15] also suggested that anabolic agents would be a more plausible approach to the management of adynamic bone disease, an example of very low bone turnover state. Furthermore, there was one case report which improved skeletal mineralization effectively by hPTH (1-34) in adult hypophosphatasia characterized by severe impairment of mineralization [6] . Meanwhile, we believe that hPTH 
